Literature DB >> 29643113

Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.

Giovanni Vitale1,2, Alessandra Dicitore2, Concetta Sciammarella3, Sergio Di Molfetta4, Manila Rubino5, Antongiulio Faggiano3, Annamaria Colao3.   

Abstract

Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  neuroendocrine tumors; pasireotide; somatostatin analogs; somatostatin receptors

Mesh：

Substances：

Year:  2018        PMID： 29643113     DOI： 10.1530/ERC-18-0010

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  6 in total

Review 1.  Treatment personalization in gastrointestinal neuroendocrine tumors.

Authors:  Chiara Borga; Gianluca Businello; Sabina Murgioni; Francesca Bergamo; Chiara Martini; Eugenio De Carlo; Elisabetta Trevellin; Roberto Vettor; Matteo Fassan
Journal:  Curr Treat Options Oncol       Date:  2021-02-27

2.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

3.  Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.

Authors:  Kristof Harda; Zsuzsanna Szabo; Erzsebet Szabo; Gabor Olah; Klara Fodor; Csaba Szasz; Gabor Mehes; Andrew V Schally; Gabor Halmos
Journal:  Molecules       Date:  2018-06-26       Impact factor: 4.411

4.  Pasireotide: A Novel Treatment for Tumor-Induced Hypoglycemia Due to Insulinoma and Non-Islet Cell Tumor Hypoglycemia.

Authors:  Mahwash Siddiqui; Amy Vora; Sadia Ali; Jessica Abramowitz; Sasan Mirfakhraee
Journal:  J Endocr Soc       Date:  2020-11-05

Review 5.  Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.

Authors:  Mayank Patel; Isabel Tena; Abhishek Jha; David Taieb; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

6.  Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature.

Authors:  Hasan Husni; Sara A Khan; Buraq Alghaieb; Mohammed S Abusamaan; Thomas W Donner; Amir H Hamrahian
Journal:  Clin Case Rep       Date:  2022-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.